Skip to main content
Premium Trial:

Request an Annual Quote

Germany's Merck to Use Cenix's RNAi Service to Screen for Drugs

NEW YORK (GenomeWeb News) – Cenix BioScience today said German drug maker Merck will use its RNAi screening services in its target-discovery and -validation efforts in oncology, with an option to expand in several human disease programs.
 
Terms of the deal call for Cenix to perform high-throughput screens of cultured human cells to discover and validate new therapeutic targets, using assays co-designed with Merck scientists.
 
Financial terms of the deal were not disclosed.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.